Sibeprenlimab, a IgG2 monoclonal antibody that binds to a proliferation-inducing ligand may treat patients with high-risk IgA nephropathy. Sibeprenlimab, a IgG2 monoclonal antibody that binds to a proliferation-inducing ligand, may treat IgA nephropathy.
Sibeprenlimab, a IgG2 monoclonal antibody that binds to a proliferation-inducing ligand may treat patients with high-risk IgA nephropathy. Sibeprenlimab, a IgG2 monoclonal antibody that binds to a proliferation-inducing ligand, may treat IgA nephropathy.
Key Highlights: Continued progress has been made in advancing an investigator-initiated clinical trial to gain human proof-of-concept for Cholesterol Efflux Mediator™ VAR 200 in patients with. | May 12, 2023